Table 3.
Patient characteristics
| Characteristic | Total events (n = 169) |
ADEs (n = 88) |
Potential ADEs (n = 81) |
|---|---|---|---|
| Age, mean +/- SD | 68.1 +/- 13.2 (range 36-95) |
69.5 +/- 13.5 (range 37-90) |
66.6 +/- 12.8 (range 36-95) |
| Insurance, No. (%) | |||
| Private | 32 (18.9%) | 19 (21.6%) | 13 (16.0%) |
| Private/Medicare | 100 (59.2%) | 52 (59.1%) | 48 (59.3%) |
| Private/Medicaid | 3 (1.8%) | 0 | 3 (3.7%) |
| Medicare | 12 (7.1%) | 7 (8.0%) | 5 (6.2%) |
| Medicare/Medicaid | 14 (8.3%) | 7 (8.0%) | 7 (8.6%) |
| Medicaid | 8 (4.7%) | 3 (3.4%) | 5 (6.2%) |
| Indication, No. (%) | |||
| Atrial fibrillation | 92 (54.4%) | 51 | 41 |
| Deep vein thrombosis | 46 (27.2%) | 19 | 27 |
| Pulmonary embolism | 26 (15.4%) | 13 | 13 |
| Stroke | 23 (13.6%) | 15 | 8 |
| Valve replacement | 23 (13.6%) | 11 | 12 |
| Hypercoagulable | 11 (6.5%) | 3 | 8 |
| Other | 10 (5.9%) | 4 | 6 |
| Indeterminate | 1 (0.6%) | 0 | 1 |
| None | 1 (0.6%) | 1 | 0 |
| Duration of warfarin therapy, No. (%) | |||
| <1 mo | 25 (14.8) | 12 (13.6) | 13 (16.0) |
| 1-3 mos | 17 (10.1) | 8 (9.1) | 9 (11.1) |
| 4-6 mos | 9 (5.3) | 3 (3.4) | 6 (7.4) |
| 7-12 mos | 11 (6.5) | 8 (9.1) | 3 (3.7) |
| 1-5 y | 29 (17.2) | 13 (14.8) | 16 (19.8) |
| > 5 y | 25 (14.8) | 15 (17.0) | 10 (12.3) |
| Indeterminate | 52 (30.8) | 28 (31.8) | 24 (29.6) |
| No prescribed warfarin | 1 (0.6) | 1 (1.1) | 0 |
| Seen at Duke clinic or hospital within 30 d, No. (%)* | 115 (73.2%) | 52 (65.0%) | 63 (81.8%) |
| Anticoag. therapy addressed within 30 d, No. (%)* | 90 (57.3%) | 43 (53.8%) | 47 (61.0%) |
*Denominator limited to events with a prior encounter note present in the EHR:
Total events = 157, ADEs = 80, pADE = 77.